Cargando…
Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
Glioblastoma is the most common and malignant brain cancer in adults. Current therapy consisting of surgery followed by radiation and temozolomide has a moderate success rate and the tumor reappears. Among the features that a cancer cell must have to survive the therapeutic treatment and reconstitut...
Autores principales: | Garros-Regulez, Laura, Garcia, Idoia, Carrasco-Garcia, Estefania, Lantero, Aquilino, Aldaz, Paula, Moreno-Cugnon, Leire, Arrizabalaga, Olatz, Undabeitia, Jose, Torres-Bayona, Sergio, Villanua, Jorge, Ruiz, Irune, Egaña, Larraitz, Sampron, Nicolas, Matheu, Ander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075570/ https://www.ncbi.nlm.nih.gov/pubmed/27822457 http://dx.doi.org/10.3389/fonc.2016.00222 |
Ejemplares similares
-
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
por: Garros-Regulez, Laura, et al.
Publicado: (2016) -
Oncogenic activity of SOX1 in glioblastoma
por: Garcia, Idoia, et al.
Publicado: (2017) -
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2019) -
PR-LncRNA signature regulates glioma cell activity through expression of SOX factors
por: Torres-Bayona, Sergio, et al.
Publicado: (2018) -
Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors
por: Torres-Bayona, Sergio, et al.
Publicado: (2022)